Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Gliosarcoma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Dimethyl Fumarate × Clear all
NCT06705608 2024-11-26

MS; FTY720

University of British Columbia

Completed
4,000 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

NCT02546440 2023-03-31

DMF-CTCL

Universitätsmedizin Mannheim

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT02337426 2019-06-28

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Virginia Commonwealth University

Phase 1 Completed
12 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡